Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis

Kamarajah, Sivesh K.; Frankel, Timothy L.; Sonnenday, Christopher J.; Cho, Clifford S.; Nathan, Hari

doi:10.1002/jso.24908

Cited by 125 publications

(103 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TNM staging system is a frequently used pathological staging system of HCC that is based on the biological behavior of the tumor . Consistent with the Barcelona Clinic Liver Cancer staging system, the TNM staging system defines a single nodule HCC up to 2 cm as the criterion for very early stage HCC .…”

Section: Discussionmentioning

confidence: 99%

“…T HE TNM STAGING system is a frequently used pathological staging system of HCC that is based on the biological behavior of the tumor. 21 Consistent with the Barcelona Clinic Liver Cancer staging system, the TNM staging system defines a single nodule HCC up to 2 cm as the criterion for very early stage HCC. 22 Based on a multicenter clinical retrospective study, the 8th Edition of the American Joint Committee on Cancer Staging Manual no longer discusses the prognostic impact of MVI on this type of HCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis

Wang

2018

Hepatology Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis

Wang

2018

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Other variables of interest were age, sex, tumour diameter, laboratory variables, type of surgery (categorized according to types of liver resection), length of hospital stay, need for surgical re‐intervention, microscopic tumour vascular invasion, lymph node invasion, stage of the disease (American Joint Commission on Cancer (AJCC)), follow‐up time and operative mortality.…”

Section: Methodsmentioning

confidence: 99%

“…These range from alterations in liver function, appearance of ascites, coagulopathy, encephalopathy and jaundice not associated with biliary obstruction or leakage, 18 using the classification of the International Study Group of Liver Surgery (ISGLS). 19 Other variables of interest were age, sex, tumour diameter, laboratory variables, type of surgery (categorized according to types of liver resection), length of hospital stay, need for surgical re-intervention, microscopic tumour vascular invasion, lymph node invasion, stage of the disease (American Joint Commission on Cancer (AJCC)), 20 follow-up time and operative mortality.…”

Section: Variablesmentioning

confidence: 99%

Surgical treatment results of hepatocellular carcinoma in non‐cirrhotic liver in southern Chile: case series with follow‐up

Manterola

Grande

Otzen

et al. 2019

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background Hepatocellular carcinoma is the most frequent primary tumour of the liver. Although often associated with chronic liver disease, it can also occur in non‐cirrhotic livers. The aim of this study was to describe post‐operative morbidity (POM), and survival of patients with hepatocellular carcinoma in non‐cirrhotic liver treated surgically, and to identify variables associated with prognosis. Methods Case series of patients who underwent surgery for hepatocellular carcinoma in non‐cirrhotic liver at Clínica RedSalud Mayor de Temuco, Chile (2001–2017), were studied. The minimum follow‐up time considered was 12 months. Principal outcomes were development of POM and survival. Other variables of interest were age, sex, tumour diameter, surgical time, hospital stay, follow‐up time, need for surgical re‐intervention, mortality, vascular and lymph node invasion and staging. Descriptive and analytic statistics were calculated. Results A total of 32 patients were studied. They were characterized by a mean age of 67.3 ± 7.2 years, 62.5% of whom were men. Averages of tumour diameter, surgical time and hospitalization were 12.0 ± 2.6 cm, 114.4 ± 32.3 min and 7.2 ± 2.9 days, respectively. POM was 31.3%. There was no mortality and there were no re‐interventions. The overall actuarial survival at 1, 2 and 3 years was 96.8%, 73.4% and 17.3%, respectively. Lower survival was verified in patients with vascular invasion, lymph node infiltration and stages III and IVa. Conclusion Despite the tumour diameter and extent of the resections, POM in patients with hepatocellular carcinoma in non‐cirrhotic liver is moderate. However, its prognosis is poor. Vascular invasion, lymph node invasion and advances stages were associated with worse survival.

show abstract

“…Liver nodules, more than 1 cm should be scanned with dynamic least one of them is more than 5 cm, while the T4 disease related to major vascular invasion [37] .…”

Section: Hcc Diagnosis In Ct and Mrimentioning

confidence: 99%

Current Status Regarding Tumour Progression, Surveillance, Diagnosis, Staging, and Treatment Of HCC: A Literature Review

Ahmad¹,

Suardi²,

Shukri³

et al. 2019

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary malignant tumour of the liver, and is globally considered to be a major causes of cancer-associated mortality. The early diagnosis of HCC improves overall survival through the application of suitable treatment options. This article presents some of the techniques for the surveillance of HCC like ultrasonography and the use of tumour biomarkers such as α-fetoprotein (AFP), DesGamma-Carboxy Prothrombin (DCP) and others. Included in the discussion will be diagnostic methods like computed tomography (CT), magnetic resonance imaging (MRI), contrast enhancement ultrasound (CEUS), and fluorodeoxyglucose positron emission tomography hybrid with computed tomography (FDG PET/CT). Current molecular pathogenesis related to HCC and the molecular steps that determine the transition from benign to malignancy are also analysed. The HCC stages which depends on the Barcelona Clinic Liver Cancer (BCLC) algorithm are also discussed. Finally, this review article discusses the present therapeutic and treatment options for HCC such as resection, transplantation, or ablation used to treat early stage cancer. Also included will be trans-arterial chemoembolization (TACE) and Sorafenib for patients with intermediate and advanced-stage cancer, respectively.

show abstract

Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis

Cited by 125 publications

References 17 publications

Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis

Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis

Surgical treatment results of hepatocellular carcinoma in non‐cirrhotic liver in southern Chile: case series with follow‐up

Current Status Regarding Tumour Progression, Surveillance, Diagnosis, Staging, and Treatment Of HCC: A Literature Review

Contact Info

Product

Resources

About